The stock our RS Engine just flagged near a level that matters

What the system saw

IOVA is sitting in the 98.5th percentile for relative strength over the last 63 days. Read that again — out of everything in the universe our system scans, this name has been outperforming nearly all of it. And right now, it's resting on its 20-day moving average, almost to the penny. Today's low was $8.12. The 20dma is $8.08. It held. We're in. The Relative Strength Engine scored it 73.8 out of 100. Not the highest conviction we've ever seen, but solidly in the range where we act. The score pulls from a handful of inputs — the RS rank alone contributes 37 points, and proximity to support, plus the fact that it held that level, chips in another 23 or so. Clean setup. Clean signal.

Why our Relative Strength Engine liked it

The logic here is straightforward: strong stocks that pull back to support and hold tend to resume their trend. IOVA has been one of the strongest names in our scan for the better part of three months. When something that strong dips to its 20dma and refuses to break, that's worth a closer look. The fundamentals aren't why we're here — and it's worth saying that plainly. IOVA is a clinical-stage biotech carrying net margins of -89%, negative ROE, and negative ROIC. It burns cash. A DCF-based fair value lands around $4, and the average analyst price target sits at $7.83, which is actually slightly below where it's trading now. The Piotroski F-Score is a middling 4 out of 9. None of that is surprising for a biotech at this stage, but it does mean the stock is being carried by momentum and sentiment, not earnings. One real positive: the Altman Z-Score of 7.8 says it's not in financial distress — meaningful given the burn rate. Revenue is growing fast, and EPS losses are narrowing year over year. There's a story here. We're just not betting on the story. We're betting on the chart.

The trade plan

Here's how the Relative Strength Engine sized this one: - Entry: $8.15 - Stop: $7.48 — just below recent structure - Target: $9.51 (that's roughly 2R) - Risk per share: $0.67 We're putting about $4,931 behind it — 605 shares in the paper account. The stop sits $0.67 below entry. If price gets there, we're out. No deliberating, no second-guessing. The target at $9.51 gives us a clean 2-to-1 reward-to-risk ratio if the bounce follows through.

Position size: our paper account is putting about $4,931 (605 shares) into this trade, sized to risk roughly $405 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

A few things deserve your attention before you get excited about the setup. The win rate on this system is sitting at 0% through 17 closed trades on Day 49. That's a real number, and we're putting it right in front of you. Most open positions are in CRNX, which continues to drift slightly positive, while NWL carries the real pain at -3.9%. IOVA is a biotech, which means news risk is always in the room — a trial readout or FDA update can gap the stock well past any stop before you can react. The Relative Strength Engine reads price behavior; it doesn't predict catalysts. Volume dried up on the pullback, which scored well in our model, but thin volume cuts both ways — any overnight development can move this thing fast in either direction.

One more thought before we go

IOVA has been testing this 20dma level for a few sessions now, and it keeps finding buyers. The fact that it's still holding while the broader market does essentially nothing — SPY up 0.01% — actually sharpens the relative strength case rather than softening it. When the market finally picks a direction, the names sitting at the top of the RS rankings tend to move first and move harder. We'll find out soon enough whether IOVA is still one of them.